TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03665285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318
Description: NC318 is an experimental antibody drug that may make the immune response more active against cancer.
Study: NCT01244880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline infusion for 56 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: PF-02545920 10 mg single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: PF-02545920 10 mg tablet single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline infusion for 56 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet single dose
Study: NCT02475642

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVI-ADT
Description: Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVI+ADT
Description: Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
Study: NCT03077568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Stress Control
Description: The web-based program is designed to educate the users in how stress can affect their health, provide tools to handle stress and also educate the users in a problem-solving method to prevent and manage stress-related problems in the future.~The program is tailored for each user. The stress-management techniques included are: assertiveness training, change negative thinking, pleasant activity scheduling, relaxation, time-management, stimulus control and sleep restriction to improve sleep and physical activity.~Central techniques to support behaivor change in My Stress Controll are encourage intention formulation, specific goal-setting, feedback on performance and reevaluation of goals.
Study: NCT03188952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: International Caries Classification and Management System
Description: Caries assessment and management system

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: International Caries Classification and Management System
Description: Caries assessment and management system
Study: NCT02691780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study: NCT02793232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 single dose
Description: PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo single dose
Description: Matched Placebo suspension administered as single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 multiple ascending dose
Description: PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple ascending dose
Description: Matched placebo suspension administered daily for 14 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979 multiple dose
Description: PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple elderly dose
Description: Multiple dose administration to Healthy Elderly Subjects (Placebo)
Study: NCT03602287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 2% Injection 20Ml Vial (Product)
Description: 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
Study: NCT03640871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGO AWC_019 dressing (AWC=Advanced Wound Care)
Description: URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)
Study: NCT01615848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean diet restricted calorie
Description: 1500 k/cal 30% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: 50 pcos diagnosed women will be assigned to high protein diet for 18 month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean diet restricted calorie
Description: 50 pcos women will be assigned to 1500 k/cal diet for 18 month
Study: NCT04961606

Intervention type: OTHER
Intervention: interview
Description: semi-structured individual interview

Intervention type: OTHER
Intervention: interview
Description: semi-structured individual interview
Study: NCT02527980

Intervention type: OTHER
Intervention: No intervention: observation only
Description: For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.

Intervention type: OTHER
Intervention: No intervention: observation only
Description: For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
Study: NCT02682901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloset
Description: Cycloset 1.6 -3.2 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo for cycloset
Study: NCT01868100

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: self-completion questionnaire
Study: NCT01443533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARC Script
Description: The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
Study: NCT01306227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Thyroxine
Description: Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
Study: NCT03870555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 infusion administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954 Placebo
Description: TAK-954 placebo-matching infusion intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954 Placebo
Description: TAK-954 placebo-matching infusion intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954 Placebo
Description: TAK-954 placebo-matching infusion intravenous.
Study: NCT01445769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 \& 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10\^9/L at wk 12 or ≥ 150 x 10\^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
Study: NCT03238105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioglycolic Acid
Description: Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: Monthly sessions for 3 months.
Study: NCT02444273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will be given and individualized exercise program.
Study: NCT04511728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h
Study: NCT02525159

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DIM pills
Description: Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
Study: NCT00531804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gantenerumab
Description: Administered iv at escalating doses (7 cohorts)
Study: NCT01400451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (BMS-734016)
Description: Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
Study: NCT01327651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily dosing
Description: A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Time-driven dosing
Description: TDF/FTC twice weekly with a post-exposure dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Event-driven dosing
Description: TDF/FTC as needed with a post exposure dose
Study: NCT01871584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colon cleansing by hydrotherapy
Description: The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon cleansing by hydrotherapy
Description: The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
Study: NCT02950220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03954600

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: NPT520-34 (125 mg)
Description: NPT520-34, 125 mg oral capsules (size 1)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos (125 mg)
Description: Placebo, 125 mg oral capsules
Study: NCT02656602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction
Description: The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
Study: NCT03378908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Treatment
Description: Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
Study: NCT02848196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
Study: NCT00262873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study: NCT04620460

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-intensity Focused Ultrasound(LIFUS)
Description: Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity Focused Ultrasound(LIFUS)
Description: Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
Study: NCT01890421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, Gadavist, BAY86-4875)
Description: Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
Study: NCT02103530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
Study: NCT04327388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study: NCT03310970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 5% patch
Description: Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine hydrochloride
Description: Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidoderm 5% patch
Description: Each subject will wear three Lidoderm® topical patches for 12 hours.
Study: NCT04219423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal physical therapy
Description: see description in arm/group description
Study: NCT03979274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Eutirox®
Description: Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Eutirox®
Description: Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Eutirox®
Description: Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Eutirox®
Description: Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
Study: NCT04963257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline fluvoxamine
Description: the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions